♟ Biotech Sector Stands to Win As Fed Rate-Cut Cycle Begins

11.4% Biotech Boost: Profit from Rate Cuts While Others Lag Behind ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

View in browser Editor's Note: Millionaire Trader Nate Bear has just opened his popular private chat room for FREE, and it started today! Don't worry, you haven't missed out - there's still plenty of time to join the action! Nate's FREE Daily Profits Live Open House kicked off this morning at 9 AM ET (Sept 9th) and runs all week through September 13th. You can jump in right now for a full week of LIVE trading. No credit card required, no limits - just dive into a FULL week of trading excitement! This is an incredibly rare chance to gain FREE access to one of the top trading rooms out there. During his last open house, members had the opportunity to benefit from his 1,129% trade idea in just 2 days! Click here to RSVP NOW - It's completely FREE! The Daily Profits Live Room is already buzzing with activity. Join us now and catch the rest of today's session! -Ryan Fitzwater, Publisher "It could be the cheapest biotech stock on the market right now – which could lead to a nice play headed into a stronger interest-rate environment for biotech stocks." Bryan Bottarelli, Head Trade Tactician, Monument Traders Alliance Now that the Fed has all but handed us their rate-cutting intentions, let's continue to forecast – and position ourselves in – the companies and sectors poised to win. Today, I'd like to introduce a bullish forecast for the Biotech sector. Here's the rationale: With rates at a 20-year high, the potential for the first rate cut in 4 years could catalyze a better operating environment for the biotech sector You see, with rates so high, a collection of the top biotech stocks has gained only +4.6% annualized over the last 5 years – while the S&P 500 has gained +16%. That's dramatic under-performance. Why is that? Nearly 80% of the companies in the SPDR S&P Biotech ETF (XBI) must raise cash to continue their research and development initiatives and create new drug candidates and trial results. A downtick in rates will significantly help their burn rates. Case in Point: The XBI has a very strong negative correlation to interest rates. In other words, when rates are rising, this sector tends to underperform. And when rates are falling, this sector tends to outperform. Headed into 2025, the business environment should only get stronger for the entire biotech sector. Strange Zero Day (0DTE) Trade Wins in Surges... AND Crashes Every Time The Government Releases Jobs, Inflation, GDP, and Other Economic Reports... Use The Zero Day Loophole to target up to 253%... 327%... Even 383% overnight gains... Whether the market surges... or crashes! Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!) The same bullishness should apply to the iShares Biotechnology ETF (IBB) as well. One Specific Name I Like: Gilead Sciences (GILD). This past week, shares traded at their highest levels since January, and could be ready to approach recent highs around $85. If you recall, GILD was so good at their job – that they cured Hepatitis C- and the stock suffered because they eliminated their drug's revenue stream. As a result, the stock has largely been range-bound since 2016. With the stock trading at 13x their 12-month forward earnings, they're getting zero credit for their pipeline. That's why many consider GILD to be a low-expectation, inexpensive, and under-owned stock. It could be the cheapest biotech stock on the market right now – which could lead to a nice play headed into a stronger interest-rate environment for biotech stocks. YOUR ACTION PLAN Earlier today, I initiated a new trade inside The War Room to get positioned in the biotech sector. Is the trade on XBI? Or IBB? Or was it on GILD – or maybe a different biotech stock altogether? There's only one way to find out. Click here to Join us inside The War Room – and start trading alongside our elite group of traders! P.S. Special Invitation! Join Us In Person at Our September Meet-Up! When: Thursday, September 26th from 6:00 PM to 9:00 PM CST Where: Rivers Casino, 3000 S. River Road Des Plaines, IL 6001 It's Free! Just Click Here to RSVP & You're Confirmed! INSIGHTS YOU MAY HAVE MISSED How to Find "Bob-Ross-like" Calmness as a Trader How David Beat Goliath: $650 to $7,988 in 48 Hours One Way to Work Tanking Markets in Your Favor A Golden Opportunity Amidst Market Turbulence The David to Nvidia's Goliath: Tiny Startup Solving AI's Biggest Challenge While Nvidia grabs the headlines, a little-known company is quietly reshaping the AI landscape. Their cutting-edge technology is tackling the biggest bottleneck in AI adoption, attracting customers like Intel, AMD, Microsoft, and more. As the AI boom accelerates, this tiny startup could be the ultimate winner. Get in early on the AI revolution's best-kept secret. Follow Us on Instagram! FACEBOOK YOUTUBE   Monument Traders Alliance, LLC   You are receiving this email because you subscribed to Trade of the Day. To unsubscribe from Trade of the Day, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Forgot your password? Click here to reset it. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2024 Monument Traders Alliance, LLC | All Rights Reserved Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.